India Not Target Of U.S. FDA Witch-Hunt, Analysts Say
This article was originally published in PharmAsia News
Executive Summary
India drug makers should not feel they are being singled out for extra scrutiny by the U.S. FDA, analysts say, the nation just has the second largest number of production plants approved by the agency.